The global perfusion systems market is largely fueled by the increasing prevalence of cardiovascular disorders and the growing number of cardiac surgeries performed worldwide. In addition, the rising ...

GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results ...

The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, ...

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...

Cleveland-based University Hospitals Harrington Heart & Vascular Institute has become the first site in Ohio to clinically administer Flyrcado for the detection of coronary artery disease and arterial ...

GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter ...

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISH ...